vs
Side-by-side financial comparison of LINKBANCORP, Inc. (LNKB) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
LINKBANCORP, Inc. is the larger business by last-quarter revenue ($46.0M vs $28.1M, roughly 1.6× ARS Pharmaceuticals, Inc.). LINKBANCORP, Inc. runs the higher net margin — 6.4% vs -147.1%, a 153.5% gap on every dollar of revenue. On growth, LINKBANCORP, Inc. posted the faster year-over-year revenue change (7.3% vs -67.6%).
LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
LNKB vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.0M | $28.1M |
| Net Profit | $2.9M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 8.5% | -147.6% |
| Net Margin | 6.4% | -147.1% |
| Revenue YoY | 7.3% | -67.6% |
| Net Profit YoY | -61.2% | -182.8% |
| EPS (diluted) | $0.08 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $46.0M | $28.1M | ||
| Q3 25 | $44.8M | $32.5M | ||
| Q2 25 | $42.3M | $15.7M | ||
| Q1 25 | $53.4M | $8.0M | ||
| Q4 24 | $42.9M | $86.6M | ||
| Q3 24 | $42.9M | $2.1M | ||
| Q2 24 | $41.3M | $500.0K | ||
| Q1 24 | $40.5M | $0 |
| Q4 25 | $2.9M | $-41.3M | ||
| Q3 25 | $7.8M | $-51.2M | ||
| Q2 25 | $7.4M | $-44.9M | ||
| Q1 25 | $15.3M | $-33.9M | ||
| Q4 24 | $7.6M | $49.9M | ||
| Q3 24 | $7.1M | $-19.1M | ||
| Q2 24 | $5.8M | $-12.5M | ||
| Q1 24 | $5.7M | $-10.3M |
| Q4 25 | 8.5% | -147.6% | ||
| Q3 25 | 22.3% | -163.7% | ||
| Q2 25 | 22.4% | -302.9% | ||
| Q1 25 | 36.0% | -466.3% | ||
| Q4 24 | 22.6% | 54.5% | ||
| Q3 24 | 21.3% | -1051.6% | ||
| Q2 24 | 18.0% | -3068.0% | ||
| Q1 24 | 18.1% | — |
| Q4 25 | 6.4% | -147.1% | ||
| Q3 25 | 17.5% | -157.4% | ||
| Q2 25 | 17.5% | -285.6% | ||
| Q1 25 | 28.7% | -425.7% | ||
| Q4 24 | 17.7% | 57.7% | ||
| Q3 24 | 16.5% | -925.0% | ||
| Q2 24 | 14.1% | -2503.2% | ||
| Q1 24 | 14.1% | — |
| Q4 25 | $0.08 | $-0.41 | ||
| Q3 25 | $0.21 | $-0.52 | ||
| Q2 25 | $0.20 | $-0.46 | ||
| Q1 25 | $0.41 | $-0.35 | ||
| Q4 24 | $0.21 | $0.52 | ||
| Q3 24 | $0.19 | $-0.20 | ||
| Q2 24 | $0.16 | $-0.13 | ||
| Q1 24 | $0.15 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.3M | $245.0M |
| Total DebtLower is stronger | $177.3M | $96.4M |
| Stockholders' EquityBook value | $306.4M | $114.3M |
| Total Assets | $3.1B | $327.7M |
| Debt / EquityLower = less leverage | 0.58× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.3M | $245.0M | ||
| Q3 25 | $194.2M | $288.2M | ||
| Q2 25 | $155.1M | $240.1M | ||
| Q1 25 | $220.2M | $275.7M | ||
| Q4 24 | $166.1M | $314.0M | ||
| Q3 24 | $191.2M | $204.6M | ||
| Q2 24 | $181.7M | $218.7M | ||
| Q1 24 | $172.3M | $223.6M |
| Q4 25 | $177.3M | $96.4M | ||
| Q3 25 | $102.3M | $96.2M | ||
| Q2 25 | $102.3M | — | ||
| Q1 25 | $102.7M | — | ||
| Q4 24 | $112.5M | $0 | ||
| Q3 24 | $102.4M | — | ||
| Q2 24 | $102.3M | — | ||
| Q1 24 | $102.2M | — |
| Q4 25 | $306.4M | $114.3M | ||
| Q3 25 | $305.5M | $147.7M | ||
| Q2 25 | $298.0M | $192.3M | ||
| Q1 25 | $294.1M | $229.0M | ||
| Q4 24 | $280.2M | $256.8M | ||
| Q3 24 | $277.4M | $201.0M | ||
| Q2 24 | $271.4M | $215.2M | ||
| Q1 24 | $268.2M | $223.9M |
| Q4 25 | $3.1B | $327.7M | ||
| Q3 25 | $3.1B | $372.8M | ||
| Q2 25 | $2.9B | $313.5M | ||
| Q1 25 | $2.9B | $327.3M | ||
| Q4 24 | $2.9B | $351.2M | ||
| Q3 24 | $2.9B | $217.6M | ||
| Q2 24 | $2.9B | $222.0M | ||
| Q1 24 | $2.8B | $227.6M |
| Q4 25 | 0.58× | 0.84× | ||
| Q3 25 | 0.33× | 0.65× | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.40× | 0.00× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.38× | — | ||
| Q1 24 | 0.38× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $25.3M | $-43.5M |
| Free Cash FlowOCF − Capex | $23.8M | — |
| FCF MarginFCF / Revenue | 51.7% | — |
| Capex IntensityCapex / Revenue | 3.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 8.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.3M | $-43.5M | ||
| Q3 25 | $23.6M | $-47.0M | ||
| Q2 25 | $6.3M | $-39.6M | ||
| Q1 25 | $2.6M | $-40.7M | ||
| Q4 24 | $25.4M | $42.0M | ||
| Q3 24 | $14.0M | $-14.5M | ||
| Q2 24 | $6.4M | $-7.3M | ||
| Q1 24 | $-771.0K | $-6.7M |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $23.2M | $-47.2M | ||
| Q2 25 | $6.1M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.8M | ||
| Q4 24 | $22.6M | $41.7M | ||
| Q3 24 | $13.1M | $-14.6M | ||
| Q2 24 | $6.3M | $-7.3M | ||
| Q1 24 | $-1.2M | $-6.8M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 51.8% | -145.4% | ||
| Q2 25 | 14.5% | -252.2% | ||
| Q1 25 | 4.2% | -512.1% | ||
| Q4 24 | 52.6% | 48.2% | ||
| Q3 24 | 30.5% | -706.3% | ||
| Q2 24 | 15.3% | -1463.4% | ||
| Q1 24 | -3.0% | — |
| Q4 25 | 3.2% | 0.0% | ||
| Q3 25 | 0.8% | 0.6% | ||
| Q2 25 | 0.4% | 0.3% | ||
| Q1 25 | 0.7% | 1.1% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 2.1% | 6.8% | ||
| Q2 24 | 0.1% | 7.6% | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 8.59× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 3.35× | 0.84× | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LNKB
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
